CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. The company was founded in1995 and is headquartered in Boston, MA.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- CervoMed will present 12-week plasma biomarker results for neflamapimod in nonfluent variant primary progressive aphasia at the ISFTD Annual Meeting in October 2026. - The late-breaking oral presentation will report neurofilament light chain and glial fibrillary acidic protein data from at least 22 of the trial's 25 enrolled participants. - The Phase 2a trial, conducted at academic medical centers in the U.S. and U.K., was designed to assess safety, pharmacokinetics, and clinical effects of the oral p38 MAP kinase inhibitor. - nfvPPA, the frontotemporal dementia subtype most associated with tau pathology, affects an estimated 10,000-15,000 people in the U.S. and 15,000-20,000 in the E.U., with no approved treatments.
• Q32 Bio's bempikibart showed promise in Phase IIa trial for alopecia areata (AA), achieving a 16% mean reduction in SALT score at week 24 compared to placebo. • However, bempikibart failed its Phase IIa trial for atopic dermatitis (AD), with placebo showing slightly better improvement in EASI scores, leading to investor selloff. • BioAge Labs halted its Phase II STRIDES trial of azelaprag due to liver transaminitis, causing stock downgrade and concerns about the drug's safety profile at higher doses. • Candel Therapeutics and uniQure saw stock surges following positive trial results and FDA agreement, respectively, while CervoMed and Chimerix also experienced significant stock movements.
- CervoMed's RewinD-LB Phase 2b trial of neflamapimod in dementia with Lewy bodies (DLB) did not meet its primary or secondary endpoints. - Initial analysis suggests that target plasma drug concentrations were not achieved during the double-blind phase, impacting trial results. - The company is analyzing clinical and pharmacokinetic data and will provide an update after the open-label extension data becomes available in late Q2 2025. - Despite the setback, neflamapimod demonstrated a favorable safety and tolerability profile, with no new safety signals identified.
- The FDA has granted orphan drug designation to CervoMed's neflamapimod for frontotemporal dementia, a rare neurodegenerative disease. - CervoMed's stock price increased by 14.6% following the announcement, reflecting investor confidence in the drug's potential. - Neflamapimod, an oral p38MAP kinase alpha inhibitor, is also being studied for early-stage dementia with Lewy bodies, with Phase III trials planned. - Orphan drug designation provides CervoMed with financial incentives, including tax credits and market exclusivity, to support neflamapimod's development.
• CervoMed and Cognition Therapeutics are both advancing novel therapies for dementia with Lewy bodies (DLB) in Phase II clinical trials, addressing a significant unmet need. • DLB affects an estimated 1.4 million people in the U.S., ranking as the second most common dementia after Alzheimer's disease. • These trials represent crucial steps in developing targeted treatments for DLB, a condition for which no drugs have been specifically approved.
• CervoMed received the Prix Galien USA 2024 Best Startup award for its work on developing a treatment for Dementia with Lewy bodies (DLB). • The award recognizes CervoMed's progress with neflamapimod, currently in a Phase 2b trial (RewinD-LB) for early-stage DLB, with topline results expected in December 2024. • DLB affects over 1.4 million people in the U.S. and EU and has no approved treatments, highlighting the significant unmet medical need CervoMed is addressing. • Neflamapimod, an oral p38MAP kinase alpha inhibitor, has shown promise in improving dementia severity and functional mobility in earlier trials.
• CervoMed's neflamapimod demonstrated a significant reduction in plasma GFAP levels, a key biomarker of neurodegenerative activity in DLB patients, in a Phase 2a trial. • The reduction in GFAP levels correlated with improved clinical outcomes, suggesting neflamapimod's therapeutic effect is mediated through the basal forebrain cholinergic system. • The RewinD-LB Phase 2b trial enrolled a DLB patient population without tau pathology, potentially increasing the study's statistical power to detect treatment effects. • Topline results from the RewinD-LB Phase 2b clinical trial of neflamapimod in DLB patients are expected in December, with high statistical power anticipated.
• CervoMed's neflamapimod demonstrates potential in treating Dementia with Lewy Bodies (DLB) by reducing neurodegenerative activity in the basal forebrain cholinergic system. • Phase 2a trial data indicates that neflamapimod significantly lowers plasma GFAP levels, a key biomarker, correlating with improved clinical outcomes in DLB patients. • The RewinD-LB Phase 2b study enrolled a DLB patient population optimized to exhibit neflamapimod's treatment effect, with topline data expected in December. • By focusing on patients without tau pathology, the RewinD-LB trial aims for enhanced statistical power to detect clinically meaningful differences between neflamapimod and placebo.
• CervoMed's neflamapimod demonstrated a significant reduction in plasma GFAP levels (p=0.015 vs placebo) in Phase 2a trials, suggesting reduced neurodegenerative activity in DLB. • The ongoing RewinD-LB Phase 2b study successfully enrolled DLB patients without tau pathology, optimizing the potential treatment effect of neflamapimod. • With 80 patients per arm, the RewinD-LB Phase 2b study boasts nearly 100% statistical power for its primary endpoint, with topline results expected in December. • Neflamapimod could become a first-in-class therapy for the 1.4 million DLB patients in the U.S. and EU, addressing a significant unmet medical need.
• CervoMed's neflamapimod demonstrated a significant reduction in plasma GFAP levels, a key biomarker of neurodegenerative activity in dementia with Lewy bodies (DLB). • The reduction in GFAP levels correlated with improved clinical outcomes, suggesting neflamapimod's potential to modify disease progression in DLB patients. • The RewinD-LB Phase 2b trial enrolled a DLB patient population optimized for treatment effect by excluding those with tau pathology, enhancing the study's statistical power. • Topline results from the RewinD-LB Phase 2b clinical trial of neflamapimod are expected in December, with increased confidence due to targeted patient selection.
